Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies how well sipuleucel-T with or without tasquinimod
works in treating patients with hormone-resistant prostate cancer that has spread to other
parts of the body. Vaccines made from a person's tumor cells and white blood cells may help
the body build an effective immune response to kill tumor cells. Tasquinimod may stop the
growth of prostate cancer by blocking the growth of new blood vessels necessary for tumor
growth. It is not yet known whether sipuleucel-T is more effective with or without
tasquinimod in treating prostate cancer.